Laser eye surgery risks downplayed

  • Marie Claire is supported by its audience. When you purchase through links on our site, we may earn commission on some of the items you choose to buy.
  • Consultations are ‘flawed’ a Which? study suggests

    People may not be properly advised on the risks of laser eye surgery and might pay more than the advertised price, a Which? study suggests.

    The magazine sent researchers into 18 clinics, including several branches of three high street chains. More than half of the 18 consultations were rated unsatisfactory by the consumer group’s panel, who included a laser eye surgeon and two clinical researchers.

    They reported staff at clinics played down possible risks and complications – issues included not addressing the problem of ‘dry eyes’, and failing to mention the risk of longer-term damage dry eye surgery might cause – although there were branches of Optimax, Optical Express and Ultralase where this was raised.

    Clinics were also criticised for failing to tell researchers that as they reached middle-age they were likely to need reading glasses despite having had surgery. Which? claims almost half of their researchers were not told about this, despite asking whether they might need glasses after surgery.

    The report also pointed to discrepancies between advertised prices and actual cost. Optimax and Optical Express advertise prices from around £395 per eye – £790 for both – but the lowest price offered was £1,090 at one branch of Optical Express.

    Optical Express said the report was ‘misleading and unfair’. It noted that the £395 per eye offer had already been investigated by the Broadcast Advertising Clearance Centre and not found to be misleading, as the price was applicable to a significant number with mild visual problems.

    It also defended its policy for pre-surgery consultations as ‘robust’ and said quotes from conversations may have been taken ‘completely out of context’. ‘Some of these remarks may simply have been benign reassurance – we don’t know the full discussion,’ said Dr Steve Schallhorn, the company’s chief medical director.


    Reading now